Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Plasma from individuals who have recovered from COVID-19 could benefit sick patients, but definitive evidence for or against convalescent plasma is still lacking. A consensus about how it should be deployed is beginning to emerge—and tools and insights to guide its use are becoming available.
A deep brain stimulation device capable of fine-tuning output on the basis of patient neuronal activity has been approved for the first time for use in Parkinson’s and a range of other neurological disorders.
Coronavirus is instigating new thinking in diagnostics, such as face masks that can detect viruses on a wearer’s breath or paper-based microfluidics for pathogen identification in low-resource settings.
Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow.